PCOS Has a New Name That Aims to Improve Diagnosis and Understanding Overall!

Here’s what you need to know about PMOS, the new name for PCOS, and why it matters. South Africa (14 May 2026) – If you, or a loved one,... The post PCOS Has a New Name That Aims to Improve Diagnosis and Understanding Overall! appeared first on Good Things Guy.

May 14, 2026 - 16:13

PCOS Has a New Name That Aims to Improve Diagnosis and Understanding Overall!

Here’s what you need to know about PMOS, the new name for PCOS, and why it matters.

South Africa (14 May 2026) – If you, or a loved one, has ever been told they have PCOS, or spent years trying to get that diagnosis, this is important news. Polycystic Ovary Syndrome has a new name.

As of 2026, it’s officially being called Polyendocrine Metabolic Ovarian Syndrome, or PMOS.

The change marks a great shift in our understanding of the condition and even bigger hope in improving diagnosis and understanding of the condition overall. The ‘old’ name – Polycystic Ovary Syndrome – was never really accurate and has caused misunderstanding for decades.

As per the official The Lancet report, the word ‘polycystic’ means ‘many cysts,’ implying that the ovaries are covered in abnormal cysts. But that’s not actually what’s happening. What shows up on ultrasound are immature follicles and not pathological cysts.

That difference has caused confusion amongst healthcare professionals, policy makers and patients for decades.

“The broad clinical features of the condition are not captured in its current name, as although arrested follicular development is common, pathological ovarian cysts are not increased.” the report states. “These factors delay diagnosis—with up to 70% of affected individuals remaining undiagnosed—and also contribute to widespread knowledge gaps and patient dissatisfaction.”

Even more importantly, PCOS is not singularly an ovarian condition. It affects the entire body. It’s linked to hormonal imbalances, insulin resistance, metabolic issues, mental health struggles, skin and hair changes, and much, much more.

“PCOS has long been primarily perceived as a gynaecological or ovarian disorder; however, mounting research, evidence synthesis, and International Guidelines have shown that PCOS is underpinned by endocrine disturbances in insulin, androgens, and neuroendocrine and ovarian hormones.” the report adds.

“Features can be metabolic (ie, obesity, dysglycaemia, type 2 diabetes, hypertension, dyslipidaemia, metabolic dysfunction-associated steatotic liver disease, cardiovascular disease, and sleep apnoea), reproductive (ovulatory disturbances, irregular menstrual cycles, infertility, pregnancy complications, and endometrial cancer), psychological (depression, anxiety, poor quality of life, and eating disorders), and dermatological (acne, alopecia, and hirsutism)…BMI is generally higher in people with PCOS than in those without the condition, and contributes to its severity,” it shares, adding: “Overall, PCOS has multisystem health impacts and represents a growing health and economic burden.”

Up to 70% of people with the condition remain undiagnosed. Millions of women with unexplained symptoms have been dismissed, and have not received the help they need because of it, in part because even the name of the condition is misleading.

That’s why the new name matters so much.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) broadens understanding of the condition. ‘Polyendocrine’ acknowledges that multiple hormonal systems are involved. ‘Metabolic’ recognises its impact on things like blood sugar, weight, and cardiovascular health. ‘Ovarian’ keeps the link to the ovaries, where some of the key features of the condition still play out.

Together, these three words paint a more complete picture of what’s really going on in the bodies of the more than 170 million women affected worldwide.

The name change was a massive global effort that took years and involved thousands of voices. The process was led by Monash University’s Centre for Research Excellence in Women’s Health, the Androgen Excess and PCOS Society, and Verity, a UK-based patient charity that has long championed women with this condition.

Over the course of the project, over 20,000 people, including patients and healthcare professionals from every corner of the world, were surveyed and consulted. Workshops were held internationally. Patient groups, professional societies, and researchers all had a role in bringing about this name change which took around 14 years to achieve.

The process was guided by six key principles, being that the new name had to be scientifically accurate, easy to understand, free from stigma, culturally appropriate across different languages and communities, practical to implement, and genuinely helpful for improving care and outcomes.

“An accurate new name was prioritised over retaining the PCOS acronym or a generic name,” the report states.

Names shape how we think, how we research, and how we treat. When a condition is misnamed, it gets misunderstood by patients, by doctors, by researchers, and by the people who decide where funding goes. The old name kept PCOS boxed in as a reproductive issue, which meant the metabolic, psychological, and systemic aspects of the condition often got overlooked in clinical care, research, and policy.

A more accurate name opens doors. It leads to better research funding that covers the full picture of the condition. It will change how doctors diagnose and treat their patients. It also means that women will hopefully not have to fight to be believed when they’re struggling with things that, on the surface, don’t look ‘gynaecological.’

“This change has global implications for health-care systems, policy, and research, and for advancing understanding and treatment of the condition.”

The transition from PCOS to PMOS in healthcare will be gradual. The plan is a three-year rollover period that gives health systems, research institutions, medical guidelines, and disease classification databases time to update. This includes changes to international health coding systems, which is how conditions get tracked and funded globally.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for what was previously known as Polycystic Ovary Syndrome (PCOS). The name change was established through a rigorous global consensus process published in The Lancet in 2026. Read more about it here.